The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting
Open accessAbstract
UNLABELLED: Two bombesin analogs, Demobesin 4 and Demobesin 1, were characterized in vitro as gastrin-releasing peptide (GRP) receptor agonist and antagonist, respectively, and were compared as (99m)Tc-labeled ligands for their in vitro and in vivo tumor-targeting properties. METHODS: N(4)-[Pro(1),Tyr(4),Nle(14)]Bombesin (Demobesin 4) and N(4)-[d-Phe(6),Leu-NHEt(13),des-Met(14)]bombesin(6-14) (Demobesin 1) were characterized in vitro for their binding properties with GRP receptor autoradiography using GRP receptor-transfected HEK293 cells, PC3 cells, and human prostate cancer specimens. Their ability to modulate calcium mobilization in PC3 and transfected HEK293 cells was analyzed as well as their ability to trigger internalization of the GRP receptor in transfected HEK293 cells, as determined qualitatively by immunofluorescence microscopy and quantitatively by enzyme-linked immunosorbent assay (ELISA). Further, their internalization properties as (99m)Tc-labeled radioligands were tested in vitro in both cell lines. Finally, their biodistribution was analyzed in PC3 tumor-bearing mice. RESULTS: A comparable binding affinity with the 50% inhibitory concentration (IC(50)) in the nanomolar range was measured for Demobesin 4 and Demobesin 1 in all tested tissues. Demobesin 4 behaved as an agonist by strongly stimulating calcium mobilization and by triggering GRP receptor internalization. Demobesin 1 was ineffective in stimulating calcium mobilization and in triggering GRP receptor internalization. However, in these assays, it behaved as a competitive antagonist as it reversed completely the agonist-induced effects in both systems. (99m)Tc-Labeled Demobesin 1 was only weakly taken up by PC3 cells or GRP receptor-transfected HEK293 cells (10% and 5%, respectively, of total added radioactivity) compared with (99m)Tc-labeled Demobesin 4 (45% of total added radioactivity in both cell lines). Remarkably, the biodistribution study revealed a much more pronounced uptake at 1, 4, and 24 h after injection of (99m)Tc-labeled Demobesin 1 in vivo into PC3 tumors than (99m)Tc-labeled Demobesin 4. In vivo competition experiments demonstrated a specific uptake in PC3 tumors and in physiologic GRP receptor-expressing tissues. The tumor-to-kidney ratios were 0.7 for Demobesin 4 and 5.2 for Demobesin 1 at 4 h. CONCLUSION: This comparative in vitro/in vivo study with Demobesin 1 and Demobesin 4 indicates that GRP receptor antagonists may be superior targeting agents to GRP receptor agonists, suggesting a change of paradigm in the field of bombesin radiopharmaceuticals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
Cuttitta, F., Carney, D. N., Mulshine, J., Moody, T. W., Fedorko, J., Fischler, A., & Minna, J. D. (1985) · Nature · doi:10.1038/316823a0 · Cited by 1,349
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Reubi, J. C. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0007 · Cited by 1,131
Self-citationReubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127 · cited 1×
“The GRP receptor–binding affinity of the various compounds was determined by in vitro receptor autoradiography on cryostat sections of either well-characterized prostate carcinomas or on sections from HEK-GRPR or PC3 cell pellets as described previously (1,21, 22 ).”
MethodSelf-citationGinj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Erchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 515
Self-citationGastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.
Markwalder, R. V., & Reubi, J. C. (1999) · PubMed · Cited by 506
Self-citationEndocytosis and recycling of G protein-coupled receptors
Koenig, J. A., & Edwardson, J. M. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01091-2 · Cited by 357
Gut Peptides: Biochemistry and Physiology
Walsh, J. H., Dockray, G. J., & Mitty, R. D. (1994) · The Endocrinologist · doi:10.1097/00019616-199411000-00012 · Cited by 267
Hypothalamic Hormones and Cancer
Schally, A. V., Comaru-Schally, A. M., Nagy, A., Kovacs, M., Szepeshazi, K., Plonowski, A., Varga, J. L., & Halmos, G. (2001) · Frontiers in Neuroendocrinology · doi:10.1006/frne.2001.0217 · Cited by 254
Gastrin-Releasing Peptide Receptors in Non-Neoplastic and Neoplastic Human Breast
Gugger, M., & Reubi, J. C. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65525-3 · Cited by 248
Self-citationHypothalamic Hormones and Cancer
Treichel, J. A. (1982) · Science News · doi:10.2307/3966511 · Cited by 216
Zhang, H., Chen, J., Waldherr, C., Hinni, K., Waser, B., Reubi, J. C., & Maecke, H. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3845 · Cited by 201
Self-citation[99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging
Nock, B., Nikolopoulou, A., Chiotellis, E., Loudos, G., Maintas, D., Reubi, J., & Maina, T. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1040-x · Cited by 194
Self-citationInternalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato, R., Schulz, S., Waser, B., Eltschinger, V., Rivier, J., Wester, H.-J., Culler, M. D., Ginj, M., Liu, Q., Schönbrunn, A., et al. (2006) · PubMed · Cited by 183
Self-citationHigh expression of peptide receptors as a novel target in gastrointestinal stromal tumours
Reubi, J. C., K�rner, M., Waser, B., Mazzucchelli, L., & Guillou, L. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1476-2 · Cited by 154
Self-citationPerrin, M. H., Sutton, S. W., Cervini, L. A., Rivier, J., & Vale, W. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38013-9 · Cited by 141
Μάινα, Θ., Nock, B. A., Nikolopoulou, A., Sotiriou, P., Loudos, G. K., Maintas, D., Cordopatis, P. A., & Chiotellis, E. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0782-9 · Cited by 107
Self-citationThe Role of Anti-α-Enolase Autoantibodies in Pathogenicity of Autoimmune-Mediated Retinopathy
MAGRYS, A., ANEKONDA, T., REN, G., & ADAMUS, G. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-006-9065-8 · Cited by 95
Slow antagonist dissociation and long-lasting in vivo receptor protection
Vauquelin, G., & VANLIEFDE, I. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.05.001 · Cited by 95
Receptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin Analogs
Liu, Q., Cescato, R., Dewi, D. A., Rivier, J., Reubi, J.-C., & Schönbrunn, A. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.011767 · Cited by 93
Self-citationSleight, A. J., Stam, N. J., Mutel, V., & Vanderheyden, P. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02122-1 · Cited by 92
Localization and characterization of neuropeptide receptors in human colon
Rettenbacher, M., & Reubi, J. C. (2001) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002100100454 · Cited by 89
Self-citationFleischmann, A., Waser, B., Gebbers, J., & Reubi, J. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0964 · Cited by 47
Self-citationMichel, N., Ganter, K., Venzke, S., Bitzegeio, J., Fackler, O., & Keppler, O. T. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-02-0117 · Cited by 36
Cited by
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 963
Cancer Treatment Using Peptides: Current Therapies and Future Prospects
Thundimadathil, J. (2012) · Journal of Amino Acids · doi:10.1155/2012/967347 · Cited by 491
Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of Cancer
Fani, M., Maecke, H. R., & Okarvi, S. M. (2012) · Theranostics · doi:10.7150/thno.4024 · Cited by 333
Peptides and Peptide Hormones for Molecular Imaging and Disease Diagnosis
Lee, S., Xie, J., & Chen, X. (2010) · Chemical Reviews · doi:10.1021/cr900361p · Cited by 324
Peptide-Based Probes for Targeted Molecular Imaging
Lee, S., Xie, J., & Chen, X. (2010) · Biochemistry · doi:10.1021/bi901135x · Cited by 310
Metadata
- Authors
- Cescato, R., Maina, T., Nock, B., Nikolopoulou, A., Charalambidis, D., Piccand, V., & Reubi, J. C.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2008-01-16
- Volume
- 49
- Issue
- 2
- Pages
- 318-326
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2144240397
- Cited by
- 293
- References
- 24
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.